Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Fennec Pharmaceuticals (FENC) Operating Expenses: 2011-2025

Historic Operating Expenses for Fennec Pharmaceuticals (FENC) over the last 15 years, with Sep 2025 value amounting to $12.7 million.

  • Fennec Pharmaceuticals' Operating Expenses rose 3.90% to $12.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $43.5 million, marking a year-over-year decrease of 8.83%. This contributed to the annual value of $45.0 million for FY2024, which is 32.18% up from last year.
  • Fennec Pharmaceuticals' Operating Expenses amounted to $12.7 million in Q3 2025, which was up 2.16% from $12.4 million recorded in Q2 2025.
  • In the past 5 years, Fennec Pharmaceuticals' Operating Expenses ranged from a high of $12.7 million in Q3 2025 and a low of -$5.0 million during Q2 2022.
  • For the 3-year period, Fennec Pharmaceuticals' Operating Expenses averaged around $10.3 million, with its median value being $11.6 million (2023).
  • Its Operating Expenses has fluctuated over the past 5 years, first crashed by 227.78% in 2022, then spiked by 259.53% in 2023.
  • Over the past 5 years, Fennec Pharmaceuticals' Operating Expenses (Quarterly) stood at $4.2 million in 2021, then skyrocketed by 89.29% to $8.2 million in 2022, then soared by 40.26% to $11.6 million in 2023, then decreased by 23.32% to $8.9 million in 2024, then climbed by 3.90% to $12.7 million in 2025.
  • Its Operating Expenses stands at $12.7 million for Q3 2025, versus $12.4 million for Q2 2025 and $9.6 million for Q1 2025.